RT Journal Article
SR Electronic
T1 Highly Activated PD-1/PD-L1 Pathway in Gastric Cancer with PD-L1 Expression
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 107
OP 112
VO 38
IS 1
A1 HIROAKI SAITO
A1 YUSUKE KONO
A1 YUKI MURAKAMI
A1 YUJI SHISHIDO
A1 HIROHIKO KURODA
A1 TOMOYUKI MATSUNAGA
A1 YOJI FUKUMOTO
A1 TOMOHIRO OSAKI
A1 KEIGO ASHIDA
A1 YOSHIYUKI FUJIWARA
YR 2018
UL http://ar.iiarjournals.org/content/38/1/107.abstract
AB Background: A recent study demonstrated that immune-checkpoint molecules are associated with tumoral immune evasion. Materials and Methods: Programmed cell death protein 1 (PD-1) expression on CD4+ and CD8+ T-cells obtained from gastric cancer tissue was evaluated by multicolor flow cytometry. Immunohistochemical staining was also performed to evaluate programmed cell death ligand-1 (PD-L1) expression on gastric cancer cells. Results: There were statistically significant correlations between PD-L1 expression and age, histology, tumor size, depth of invasion, lymph node metastasis, lymphatic vessel invasion, venous invasion, and disease stage. The 5-year survival rates of patients with and without PD-L1–positive tumors were 48.9% and 80.7%, respectively, and the difference was statistically significant. Multivariate analysis indicated that PD-L1 expression was an independent prognostic indicator. The frequency of PD-1-positive CD4+ and CD8+ T-cells from gastric cancer tissue with PD-L1 expression was significantly more than that from gastric cancer tissue without PD-L1 expression. Conclusion: PD-L1 expression was related to a poor prognosis in patients with gastric cancer. Furthermore, PD-1 expression on T-cells was up-regulated in patients with tumors with PD-L1 expression.